These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 17964916)

  • 41. Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy.
    Chapman MJ; Sposito AC
    Pharmacol Ther; 2008 Mar; 117(3):354-73. PubMed ID: 18215759
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Using cardiovascular age equivalent to close the treatment gap for dyslipidemia.
    Eaton CB
    Arch Intern Med; 2007 Nov; 167(21):2288. PubMed ID: 18039985
    [No Abstract]   [Full Text] [Related]  

  • 43. Fenofibrate: treatment of hyperlipidemia and beyond.
    Rosenson RS
    Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1319-30. PubMed ID: 19018684
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Combination pharmacotherapy therapy in the management of atherogenic dyslipidemia].
    Kłosiewicz-Latoszek L; Cybulska B
    Kardiol Pol; 2005 Jun; 62 Suppl 2():II76-80. PubMed ID: 19813341
    [No Abstract]   [Full Text] [Related]  

  • 45. Viewpoint: Terje R. Pedersen, MD, PhD. Interview by Robert Short.
    Pedersen TR
    Circulation; 2007 Mar; 115(12):f51-2. PubMed ID: 17393574
    [No Abstract]   [Full Text] [Related]  

  • 46. Metabolic syndrome: diabetes and cardiovascular disease.
    Gupta S; Gupta BM
    Indian Heart J; 2006; 58(2):149-52. PubMed ID: 18989060
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Diabetic dyslipoproteinemia: beyond LDL].
    Merkel M
    Dtsch Med Wochenschr; 2009 May; 134(20):1067-73. PubMed ID: 19421932
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dyslipidaemia in diabetes.
    Patel J
    Clin Evid; 2006 Jun; (15):555-75. PubMed ID: 16973026
    [No Abstract]   [Full Text] [Related]  

  • 49. Treatment with ezetimibe in kidney transplant recipients with uncontrolled dyslipidemia.
    López V; Gutiérrez C; Gutiérrez E; Sola E; Cabello M; Burgos D; González Molina M
    Transplant Proc; 2008 Nov; 40(9):2925-6. PubMed ID: 19010149
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lipid lowering therapy for adults with diabetes.
    Jackowski L; Crockett J; Rowett D
    Aust Fam Physician; 2008; 37(1-2):39-41. PubMed ID: 18239751
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Re: Dyslipidemia is a protective factor in amyotrophic lateral sclerosis.
    Yoshii Y; Ikeda K; Iwamoto K; Kawase Y; Iwasaki Y
    Neurology; 2009 Mar; 72(10):944; author reply 944-5. PubMed ID: 19273834
    [No Abstract]   [Full Text] [Related]  

  • 52. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome.
    Davidson M
    Am J Cardiol; 2008 Dec; 102(12A):19L-27L. PubMed ID: 19084086
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluating and treating cardiometabolic risk factors: a case discussion.
    Haines ST; Fuke DC; Lender D; Rodgers PT; Sysko SK
    Pharmacotherapy; 2006 May; 26(5 Pt 2):32S-41S. PubMed ID: 16637784
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel approaches to the treatment of dyslipidemia.
    Rader DJ
    Arterioscler Thromb Vasc Biol; 2005 Mar; 25(3):480-1. PubMed ID: 15731488
    [No Abstract]   [Full Text] [Related]  

  • 55. Metabolic syndrome and insulin resistance: perioperative considerations.
    Bagry HS; Raghavendran S; Carli F
    Anesthesiology; 2008 Mar; 108(3):506-23. PubMed ID: 18292688
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rosuvastatin in hemodialysis: short-term effects on lipids and C-reactive protein.
    Burmeister JE; Miltersteiner DR; Campos BM
    J Nephrol; 2009; 22(1):83-9. PubMed ID: 19229822
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dyslipidemia and the risk of end stage renal disease.
    Haydar AA; Goldsmith DJ
    J Med Liban; 2004; 52(3):156-9. PubMed ID: 16432973
    [No Abstract]   [Full Text] [Related]  

  • 58. Pathophysiology, diagnosis, and management of dyslipidemia.
    Gau GT; Wright RS
    Curr Probl Cardiol; 2006 Jul; 31(7):445-86. PubMed ID: 16824902
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander?
    Nordestgaard BG; Zacho J
    Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):521-4. PubMed ID: 19695857
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Switching statin therapy using a pharmacist-managed therapeutic conversion program versus usual care conversion among indigent patients.
    Miller AE; Hansen LB; Saseen JJ
    Pharmacotherapy; 2008 May; 28(5):553-61. PubMed ID: 18447653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.